Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Elizabeth M. Anderson, Scott E. Hensley, Ajinkya Pattekar(University of Pennsylvania), Philip Hicks(University of Pennsylvania), Eileen C. Goodwin(University of Pennsylvania), Claudia P. Arevalo(University of Pennsylvania), Anurag Verma(Philadelphia VA Medical Center), Jennifer E. Wu(Parker Institute for Cancer Immunotherapy), Christopher M. McAllister(University of Pennsylvania), Michael R. Betts(Penn Center for AIDS Research), Nicholas Han(Translational Therapeutics (United States)), Holly Ramage(Thomas Jefferson University), Sigrid Gouma(University of Pennsylvania), Justin Kim(Translational Therapeutics (United States)), Divij Mathew(Parker Institute for Cancer Immunotherapy), Alex C. Huang(Translational Therapeutics (United States)), Marcus J. Bolton(University of Pennsylvania), Nuala J. Meyer(University of Pennsylvania), Cécile Alanio(Parker Institute for Cancer Immunotherapy), Sara Cherry(University of Pennsylvania), Derek A. Oldridge(University of Pennsylvania), Paul Bates(University of Pennsylvania), Laura A. Vella(Children's Hospital of Philadelphia), E. John Wherry(University of Pennsylvania), Jeanette Dougherty(Translational Therapeutics (United States)), Daniel J. Rader(University of Pennsylvania), M. Betina Pampena(University of Pennsylvania), Allison R. Greenplate(Vanderbilt University), Oliva Kuthuru(Translational Therapeutics (United States)), Amy E. Baxter(Translational Therapeutics (United States)), Tomaz B. Manzoni(University of Pennsylvania), Leticia Kuri-Cervantes(University of Pennsylvania), Sokratis A. Apostolidis(Harvard University), Kurt D’Andrea(University of Pennsylvania), Oluwatosin Oniyide(University of Pennsylvania), Madison E. Weirick(University of Pennsylvania), Shannon Christensen(University of Pennsylvania), JoEllen Weaver(University of Pennsylvania)
Cited by 412
Related Papers
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
|Nature Genetics|2007|1.1k